Related Experiment Video
Updated: Feb 27, 2026
06:32
Development of Human Renal Tubular Epithelial Cell Primary Cultures in Monolayers and Three-Dimensional Conditions
Published on: June 13, 2025
575
Haemolytic uraemic syndrome
1The Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, UK. ableyer@wfubmc.edu
Nephron. Clinical Practice
|November 13, 2010
Summary
Atypical hemolytic uremic syndrome (aHUS) involves complement system overactivation. Plasma exchange is a primary treatment, but newer therapies like eculizumab offer new hope for this rare disease.
Area of Science:
- Nephrology
- Immunology
- Genetics
Background:
- Atypical hemolytic uremic syndrome (aHUS) is a rare, severe thrombotic microangiopathy.
- It is characterized by dysregulation of the complement system, leading to organ damage.
- Causes include genetic mutations in complement genes and autoantibodies against complement proteins.
Purpose of the Study:
- To review the pathophysiology of aHUS.
- To discuss current and emerging therapeutic strategies for aHUS.
- To highlight the role of complement system genetics and autoimmunity.
Main Methods:
- Literature review of aHUS pathogenesis and treatment.
- Analysis of genetic and autoimmune factors contributing to complement dysregulation.
- Evaluation of plasma exchange, transplantation, and novel therapies.
Main Results:
- Inherited defects and autoantibodies against complement regulators are key triggers for aHUS.
- Plasma exchange is the current first-line therapy, removing autoantibodies and hyperactive complement.
- Renal transplantation often fails due to recurrent aHUS, with combined liver-kidney transplantation as an option.
Conclusions:
- Accurate diagnosis of the underlying defect in aHUS is crucial for predicting outcomes and guiding treatment.
- Emerging therapies, such as the complement inhibitor eculizumab, show promise for a new era in aHUS management.
- Understanding complement system dysregulation is vital for advancing aHUS treatment strategies.
Related Concept Videos
01:19Hypersensitivity Reactions: Immune-Complex Reactions
64
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
64
01:01Hypersensitivity Reactions: Cytolytic Reactions
65
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
65
01:24Hemodialysis II: Procedure and Complications
1.2K
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
1.2K
01:25Hemodialysis I: Introduction
2.3K
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
2.3K
01:23Rheumatic Heart Disease I: Introduction
641
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
641
01:24Nephrotic Syndrome I : Introduction
748
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
748